Symphony Technology Group buys majority stake in ImpactRx
ImpactRx remains part owned by the venture capital arm of drug company Merck and continues to be led by president and CEO Richard Altus (pictured).
Altus said the acquisition and investment by Symphony Technology Group will allow for further development of its capabilities to meet clients’ emerging analytical needs.
He said: “Brand teams are facing increasingly complex challenges. Understanding what drives brand performance, through all stages of the life cycle, is more critical today than it ever was.”

We hope you enjoyed this article.
Research Live is published by MRS.
The Market Research Society (MRS) exists to promote and protect the research sector, showcasing how research delivers impact for businesses and government.
Members of MRS enjoy many benefits including tailoured policy guidance, discounts on training and conferences, and access to member-only content.
For example, there's an archive of winning case studies from over a decade of MRS Awards.
Find out more about the benefits of joining MRS here.
0 Comments